Clinical trial · Interventional
Erectile Recovery After Robotic-Assisted Laparoscopic Prostatectomy
Patterns of Erectile Recovery After Robotic-Assisted Laparoscopic Prostatectomy With and Without Penile Rehabilitation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is a prospective, randomized, double-blind, placebo-controlled drug study to evaluate the pattern of erectile function recovery after robotic assisted laparoscopic prostatectomy (RALP). We hope to illustrate that early and continuous therapy with either Sildenafil citrate or pentoxyfylline after nerve sparing RALP will promote improved erectile function.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Erectile Dysfunction | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pentoxifylline | Drug | — | UNRESOLVED |
| Placebo | Other | — | UNRESOLVED |
| Sildenafil 25 MG Oral Tablet | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Sildenafil 25mg Oral Tablet
- description
- 25mg sildenafil citrate twice daily
- interventionNames
- Drug: Sildenafil 25 MG Oral Tablet
- type
- ACTIVE_COMPARATOR
- label
- Pentoxifylline
- description
- 400mg pentoxifylline twice daily
- interventionNames
- Drug: Pentoxifylline
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- placebo twice daily
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 30 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients who have had a prostate biopsy positive for prostate cancer. 2. Patient must be age 30 - 89 years. 3. Patient must be willing to sign the Institutional Review Board approved consent. 4. Patient must have had (or be about to undergo) bilateral or unilateral nerve sparing RALP. 5. Patient must have an International IIEF equal to or greater than 21. Exclusion Criteria: 1. Patients with known unstable angina, uncontrolled hypertension, congestive heart failure, or cardiovascular accident within the preceding 2 weeks. 2. Patients being treated with nitrate therapy. 3. Patients with significant renal or hepatic impairment, cerebrovascular disease. 4. Patients with prior erectile dysfunction as indicated by the initial IIEF. 5. Patients younger than 30 years of age. 6. Patients who did/will not have a unilateral or bilateral nerve sparing radical prostatectomy. 7. Patients who have had a prior reaction to Sildenafil or pentoxifylline. 8. Patients taking any potent inhibitor of cytochrome P450 3A4 (e.g., ketoconazole, itraconazole, erythromycin, etc.). 9. Patients with a clinically significant abnormality on preoperative ECG that in the opinion of the investigator may increase the patient's cardiovascular risk in this study. 10. Patients with a history of left ventricular outflow obstruction (e.g. aortic stenosis, idiopathic hypertrophic subaortic stenosis). 11. Patients with resting hypotension (BP \< 90/50 mm Hg), or resting hypertension (BP \> 170/110 mm Hg). 12. Patients with retinitis pigmentosa. 13. Patients with a bleeding disorder. 14. Patients with active peptic ulceration. 15. Patients with conditions that may predispose to priapism (e.g. sickle cell anemia, multiple myeloma, or leukemia). 16. Patients who have previously experienced non-arteritic ischemic optic neuropathy (NAION).
References
Publications (0)
Data not yet available